WO2008074036A2 - Eye medication formulation with antibacterial agent - Google Patents

Eye medication formulation with antibacterial agent Download PDF

Info

Publication number
WO2008074036A2
WO2008074036A2 PCT/US2008/000696 US2008000696W WO2008074036A2 WO 2008074036 A2 WO2008074036 A2 WO 2008074036A2 US 2008000696 W US2008000696 W US 2008000696W WO 2008074036 A2 WO2008074036 A2 WO 2008074036A2
Authority
WO
WIPO (PCT)
Prior art keywords
agent
pharmaceutically effective
effective amount
agents
anesthetic
Prior art date
Application number
PCT/US2008/000696
Other languages
French (fr)
Inventor
Ravi Nallakrishnan
Original Assignee
Ravi Nallakrishnan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ravi Nallakrishnan filed Critical Ravi Nallakrishnan
Publication of WO2008074036A2 publication Critical patent/WO2008074036A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin

Definitions

  • the present invention relates to preparations used in surgical and examination procedures in connection with the eye and, more particularly, to a formulation that includes multiple ingredients, one of which is an antibacterial agent.
  • This application claims priority from United States Patent Application serial number 61/013,232, filed December 12, 2007, which is incorporated herein by reference.
  • Dilation of the pupil of the eye is a common ophthalmic technique useful in examining the eye or in performing surgery upon the eye. Pupillary dilation gives the surgeon a greater field of vision during surgical procedures.
  • Dilation is carried out by the use of both mydriatic and cycloplegic agents, both of which cause the sphincter of the iris to open.
  • cycloplegic agents also may temporarily paralyze the lens of the eye, accompanied by loss of accommodation.
  • both such agents must penetrate the layers of the cornea, in particular the corneal epithelium order to reach the iris sphincter and the ciliary body. For topical procedures, penetration is made possible and more effective the longer the preparation remains in contact with the cornea. Where penetration is done intracamerally the agents are injected through the cornea directly into the anterior chamber.
  • One way to make the topical penetration of the selected agents more effective is to combine them in a carrier with a relatively high viscosity. This allows the agents and carrier to spread uniformly across the surface of the cornea and remain in place for a longer period of time than would be possible if the agents are applied separately or in a less viscous carrier.
  • Another frequently used agent is an anesthetic which will block any pain or other sensations caused by the use of instruments on the eye and make it possible for the patient to tolerate the examination procedure or surgical procedure.
  • an anesthetic disposed in a high- viscosity carrier is a product manufactured by CYNACON/OCuSOFT, Inc.of Rosenberg, Texas under the name TetraViscTM, which combines a high-viscosity carrier with tetracaine hydrochloride.
  • TetraViscTM a product manufactured by CYNACON/OCuSOFT, Inc.of Rosenberg, Texas under the name TetraViscTM, which combines a high-viscosity carrier with tetracaine hydrochloride.
  • NSAIA non-steroidal anti-inflammatory agent
  • a frequently-incurred problem is the presence of bacterial infections after surgery. While there are a number of effective and widely used agents available for treating such infections, I have determined that there is a benefit to be realized by including an antibacterial agent together with agents topically or intracamerally applied prior to surgery.
  • the advantages of using an antibacterial as a preventive for infection and its inclusion into a single topical formulation along with other desired or required agents makes it possible to achieve maximum penetration through the cornea by avoiding successive applications of individual agents.
  • the advantages to using an anit-bacterial agent in an intracamerally-applied combination include avoiding the necessity for a further injection or a topical application after an intracameral injection.
  • the invention is a composition or formulation for both topical and intracameral use in the eye which includes a combination of agents selected for the particular patient or procedure to be undertaken.
  • these agents include one or more of a mydriatic agent, a cycloplegic agent, a high- viscosity polymer used as a carrier and an NASIA, together with an antibacterial agent and a sufficient amount of water to give the formulation its desired consistency.
  • the active agents would be combined in a single injection in a pharmaceutically suitable carrier that can contain water and a high- viscosity polymer.
  • a first topical or intracameral formulation would include at least one of the following:
  • a pharmaceutically effective amount of a mydriatic agent a pharmaceutically effective amount of a mydriatic agent
  • the selected agent or agents would then be combined with an antibacterial agent, a viscoelastic polymer carrier and a sufficient amount of water to give the final preparation its desired flow characteristics.
  • a mydriatic agent means a sufficient amount of such an agent to cause mydriasis.
  • a pharmaceutically effective amount of a cycloplegic agent will be considered to be an amount sufficient to cause cycloplegia.
  • a pharmaceutically effective amount of an NSAIA means an amount effective to reduce or prevent unwanted swelling.
  • a pharmaceutically effective amount of an antibacterial agent means an amount of such an agent sufficient to prevent or treat a bacterial infection.
  • a pharmaceutically effective amount of an anesthetic means an amount of a selected anesthetic sufficient to reduce or eliminate patient discomfort during the procedure or examination.
  • mydriatic agents are phenylephrine, naphazoline, or epinephrine. The use of other mydriatic agents is also anticipated.
  • Suitable cycloplegic agents are tropicamide, cyclopentioate, scopolamine, homotropine and atropine. The use of other cycloplegic agents is also anticipated
  • Suitable NSAIA agents are propylmethylcelluose, methylcellulose, carboxymethylcellulose, hyaluronate and chondroitin sulfate.
  • Suitable anesthetics include many agents, examples of which are lidocaine, pilocarpine, tetracaine, proparacaine and bupivicaine. The use of other anesthetic agents is also anticipated.
  • the viscoelastic polymer used in connection with the present invention is available in a number of commercial products, a number of which used hydroxypropylmethylcellulose (HPMC). The amount of viscoelastic polymer is typically adjusted to meet the needs of the surgeon in connection and dictated by the agents in the particular formulation and the use to which they will be put.
  • HPMC hydroxypropylmethylcellulose
  • Such agents are typically identified as quinolones, a family of broad spectrum antibiotics and, in particular, fluoroquinolones which have become a community standard for use in connection with cataract surgery.
  • quinolones a family of broad spectrum antibiotics and, in particular, fluoroquinolones which have become a community standard for use in connection with cataract surgery.
  • fluoroquinolones which have become a community standard for use in connection with cataract surgery.
  • Three such antibacterial agents are moxifloxacin, sold under the
  • a desired combination including pharmaceutically effective amounts of one or more of a cycloplegic agent, a mydriatic agent or an NSAIA is combined with an antibacterial agent and a carrier suitable for intracameral injection.
  • Example 1 A pharmaceutically effective amount of a mydriatic agent is combined with a pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent in a viscoelastic carrier and is then diluted with water to a desired final viscosity.
  • Example 2 A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent and a pharmaceutically effective amount of an antibacterial agent in a viscoelastic carrier and is then diluted with water to a desired final viscosity.
  • Example 3 A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent, a pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent in a viscoelastic carrier and is then diluted with water to a desired final viscosity.
  • Example 4 A pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent are combined in a viscoelastic carrier and then diluted with water to a desired final viscosity.
  • Example 5 A pharmaceutically effective amount of an anesthetic, a pharmaceutically effective amount of a non-steroidal anti-inflammatory agent and a pharmaceutically effective amount of an antibacterial agent are combined in a viscoelastic carrier and then diluted with water to a desired final viscosity.
  • Example 6 A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent, a pharmaceutically effective amount of an anesthetic, a pharmaceutically effective amount of a non-steroidal anti-inflammatory agent and a pharmaceutically effective amount of an antibacterial agent in a viscoelastic carrier and then diluted with water to a desired final viscosity.
  • Example 7 A pharmaceutically effective amount of a mydriatic agent is combined with a pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent in a carrier suitable for intracameral injection.
  • Example 8 A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent and a pharmaceutically effective amount of an antibacterial agent in a carrier suitable for intracameral injection.
  • Example 9 A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent, a pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent in a carrier suitable for intracameral injection.
  • Example 10 A pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent are combined in a carrier suitable for intracameral injection.
  • Example 11 A pharmaceutically effective amount of an anesthetic, a pharmaceutically effective amount of a non-steroidal anti-inflammatory agent and a pharmaceutically effective amount of an antibacterial agent are combined in a carrier suitable for intracameral injection.
  • Example 12 A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent, a pharmaceutically effective amount of an anesthetic, a pharmaceutically effective amount of a non-steroidal anti-inflammatory agent and a pharmaceutically effective amount of an antibacterial agent in a carrier suitable for intracameral injection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A formulation for administration to the eye has at least one pharmaceutical agent such as a mydriatic agent, a cycloplegic agent, an anesthetic or a non-steroidal anti-inflammation agent combined with an anti-bacterial agent and a suitable carrier. The formulation can be made for topical or intracameral administration to the eye.

Description

EYE MEDICATION FORMULATION WITH ANTIBACTERIAL AGENT
Background of the Invention
[ 0001] The present invention relates to preparations used in surgical and examination procedures in connection with the eye and, more particularly, to a formulation that includes multiple ingredients, one of which is an antibacterial agent. [ 0002] This application claims priority from United States Patent Application serial number 61/013,232, filed December 12, 2007, which is incorporated herein by reference. [ 0003] Dilation of the pupil of the eye is a common ophthalmic technique useful in examining the eye or in performing surgery upon the eye. Pupillary dilation gives the surgeon a greater field of vision during surgical procedures. [ 0004] Dilation is carried out by the use of both mydriatic and cycloplegic agents, both of which cause the sphincter of the iris to open. In addition, cycloplegic agents also may temporarily paralyze the lens of the eye, accompanied by loss of accommodation. [ 0005] In order to be effective, both such agents must penetrate the layers of the cornea, in particular the corneal epithelium order to reach the iris sphincter and the ciliary body. For topical procedures, penetration is made possible and more effective the longer the preparation remains in contact with the cornea. Where penetration is done intracamerally the agents are injected through the cornea directly into the anterior chamber. [ 0006] As described in the prior art, most particularly, U.S. Patent Application
Publication US2004/0013729 (Buono) a number of advantages are gained if the topically-applied agents to be used in an eye examination or in ophthalmic surgery are applied simultaneously rather than successively. For topical applications, one advantage is that successive applications of liquids containing one or more of the needed agents will not rinse or wash away any agents that have already been infused into the eye. [ 0007] For intracameral applications, there is no necessity for multiple injections for individual agents if all are included in a single injection. [ 0008] Another advantage to delivering multiple agents in a single operation is that no large inventory of bottles of individual drugs must be purchased, maintained, tracked and timely used. [ 0009] One way to make the topical penetration of the selected agents more effective is to combine them in a carrier with a relatively high viscosity. This allows the agents and carrier to spread uniformly across the surface of the cornea and remain in place for a longer period of time than would be possible if the agents are applied separately or in a less viscous carrier. [ 0010] Another frequently used agent is an anesthetic which will block any pain or other sensations caused by the use of instruments on the eye and make it possible for the patient to tolerate the examination procedure or surgical procedure. An example of an anesthetic disposed in a high- viscosity carrier is a product manufactured by CYNACON/OCuSOFT, Inc.of Rosenberg, Texas under the name TetraVisc™, which combines a high-viscosity carrier with tetracaine hydrochloride. [ 0011] Yet another frequently used agent is a non-steroidal anti-inflammatory agent (NSAIA) used to minimize or control the swelling of tissue. [ 0012] The use of these agents such as these and their combination into a single topically applied composition is well described in the foregoing Buono reference. Those descriptions are incorporated herein by reference.
[ 0013] A frequently-incurred problem is the presence of bacterial infections after surgery. While there are a number of effective and widely used agents available for treating such infections, I have determined that there is a benefit to be realized by including an antibacterial agent together with agents topically or intracamerally applied prior to surgery. The advantages of using an antibacterial as a preventive for infection and its inclusion into a single topical formulation along with other desired or required agents makes it possible to achieve maximum penetration through the cornea by avoiding successive applications of individual agents. The advantages to using an anit-bacterial agent in an intracamerally-applied combination include avoiding the necessity for a further injection or a topical application after an intracameral injection. Brief Summary of the Invention [ 0014] Described generally, the invention is a composition or formulation for both topical and intracameral use in the eye which includes a combination of agents selected for the particular patient or procedure to be undertaken. For a topical preparation, these agents include one or more of a mydriatic agent, a cycloplegic agent, a high- viscosity polymer used as a carrier and an NASIA, together with an antibacterial agent and a sufficient amount of water to give the formulation its desired consistency. For an intracameral procedure the active agents would be combined in a single injection in a pharmaceutically suitable carrier that can contain water and a high- viscosity polymer.
[ 0015] More particularly, a first topical or intracameral formulation would include at least one of the following:
[ 0016] a pharmaceutically effective amount of a mydriatic agent;
[ 0017] a pharmaceutically effective amount of a cycloplegic agent; and [ 0018] a pharmaceutically effective amount of an NASIA.
[ 0019] The selected agent or agents would then be combined with an antibacterial agent, a viscoelastic polymer carrier and a sufficient amount of water to give the final preparation its desired flow characteristics.
[ 0020] The term "pharmaceutically effective amount" as used with respect to a mydriatic agent means a sufficient amount of such an agent to cause mydriasis.
[ 0021 ] A pharmaceutically effective amount of a cycloplegic agent will be considered to be an amount sufficient to cause cycloplegia.
[ 0022] A pharmaceutically effective amount of an NSAIA means an amount effective to reduce or prevent unwanted swelling. [ 0023] A pharmaceutically effective amount of an antibacterial agent means an amount of such an agent sufficient to prevent or treat a bacterial infection. [ 0024] A pharmaceutically effective amount of an anesthetic means an amount of a selected anesthetic sufficient to reduce or eliminate patient discomfort during the procedure or examination.
[ 0025] Examples of suitable mydriatic agents are phenylephrine, naphazoline, or epinephrine. The use of other mydriatic agents is also anticipated.
[ 0026] Examples of suitable cycloplegic agents are tropicamide, cyclopentioate, scopolamine, homotropine and atropine. The use of other cycloplegic agents is also anticipated
[ 0027] Examples of suitable NSAIA agents are propylmethylcelluose, methylcellulose, carboxymethylcellulose, hyaluronate and chondroitin sulfate.
The use of other NSAIA agents is also anticipated
[ 0028] Suitable anesthetics include many agents, examples of which are lidocaine, pilocarpine, tetracaine, proparacaine and bupivicaine. The use of other anesthetic agents is also anticipated. [ 0029] The viscoelastic polymer used in connection with the present invention is available in a number of commercial products, a number of which used hydroxypropylmethylcellulose (HPMC). The amount of viscoelastic polymer is typically adjusted to meet the needs of the surgeon in connection and dictated by the agents in the particular formulation and the use to which they will be put. [ 0030] I have determined that a number of antibacterial agents are suitable for use with the present invention. Such agents are typically identified as quinolones, a family of broad spectrum antibiotics and, in particular, fluoroquinolones which have become a community standard for use in connection with cataract surgery. [ 0031] Three such antibacterial agents are moxifloxacin, sold under the
Trademark VIGAMOX by Alcon Laboratories of Forth Worth, Texas, the agent gatifloxatin sold under the Trademark ZYMAR by Allergan, Inc. of Irvine, California, and levofloxatin sold under the trademark QUIXIN by Santen. Oy, Tampere, Finland.
[ 0032] For intracameral use, a desired combination including pharmaceutically effective amounts of one or more of a cycloplegic agent, a mydriatic agent or an NSAIA is combined with an antibacterial agent and a carrier suitable for intracameral injection. Detailed Description of the Invention
[ 0033] The following examples will demonstrate the nature of the present invention with respect to topical preparations.
[ 0034] Example 1: A pharmaceutically effective amount of a mydriatic agent is combined with a pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent in a viscoelastic carrier and is then diluted with water to a desired final viscosity.
[ 0035] Example 2: A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent and a pharmaceutically effective amount of an antibacterial agent in a viscoelastic carrier and is then diluted with water to a desired final viscosity.
[ 0036] Example 3: A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent, a pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent in a viscoelastic carrier and is then diluted with water to a desired final viscosity.
[ 0037] Example 4: A pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent are combined in a viscoelastic carrier and then diluted with water to a desired final viscosity.
[ 0038] Example 5: A pharmaceutically effective amount of an anesthetic, a pharmaceutically effective amount of a non-steroidal anti-inflammatory agent and a pharmaceutically effective amount of an antibacterial agent are combined in a viscoelastic carrier and then diluted with water to a desired final viscosity. [ 0039] Example 6: A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent, a pharmaceutically effective amount of an anesthetic, a pharmaceutically effective amount of a non-steroidal anti-inflammatory agent and a pharmaceutically effective amount of an antibacterial agent in a viscoelastic carrier and then diluted with water to a desired final viscosity. ,
[ 0040] The following examples will demonstrate the nature of the present invention with respect to intracameral preparations.
[ 0041] Example 7: A pharmaceutically effective amount of a mydriatic agent is combined with a pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent in a carrier suitable for intracameral injection.
[ 0042] Example 8: A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent and a pharmaceutically effective amount of an antibacterial agent in a carrier suitable for intracameral injection.
[ 0043] Example 9: A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent, a pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent in a carrier suitable for intracameral injection.
[ 0044] Example 10: A pharmaceutically effective amount of an anesthetic and a pharmaceutically effective amount of an antibacterial agent are combined in a carrier suitable for intracameral injection.
[ 0045] Example 11: A pharmaceutically effective amount of an anesthetic, a pharmaceutically effective amount of a non-steroidal anti-inflammatory agent and a pharmaceutically effective amount of an antibacterial agent are combined in a carrier suitable for intracameral injection. [ 0046] Example 12: A pharmaceutically effective amount of a mydriatric agent is combined with a pharmaceutically effective amount of a cycloplegic agent, a pharmaceutically effective amount of an anesthetic, a pharmaceutically effective amount of a non-steroidal anti-inflammatory agent and a pharmaceutically effective amount of an antibacterial agent in a carrier suitable for intracameral injection.
[ 0047] While the foregoing describes a preferred embodiment or embodiments of the present invention, it is to be understood that this description is made by way of example only and is not intended to limit the scope of the present invention. It is expected that alterations and further modifications, as well as other and further applications of the principles of the present invention will occur to others skilled in the art to which the invention relates and, while differing from the foregoing, remain within the spirit and scope of the invention as herein described and claimed. Where means-plus-function clauses are used in the claims such language is intended to cover the structures described herein as performing the recited functions and not only structural equivalents but equivalent structures as well. For the purposes of the present disclosure, two structures that perform the same function within an environment described above may be equivalent structures.

Claims

I claim:
1. A composition for administration to the eye, said composition comprising: at least one pharmaceutical agent in an amount to produce a desired pharmaceutical result; an antibacterial agent present in a pharmaceutically effective amount to treat or prevent bacterial infection; and a physiologically acceptable carrier for said pharmaceutical and antibacterial agents.
2. The apparatus as recited in Claim 1 wherein said pharmaceutical agent is present in a pharmaceutically effective amount and is chosen from the group of a mydriatic agent, a cycloplegic agent, an anesthetic agent or a non-steroidal anti-inflammation agent.
3. The apparatus as recited in Claim 1 wherein said composition further comprises pharmaceutically effective amounts of a mydriatic agent, a cycloplegic agent, and an anesthetic agent.
4. The apparatus as recited in Claim 1 wherein said composition further comprises pharmaceutically effective amounts of a mydriatic agent and an anesthetic agent.
5. The apparatus as recited in Claim 1 wherein said composition further comprises pharmaceutically effective amounts of a cycloplegic agent, and an anesthetic agent.
6. The apparatus as recited in Claim 1 wherein said at least one pharmaceutical agent, said carrier and said anti-bacterial agent are suitable for topical administration to said eye.
7. The apparatus as recited in Claim 1 wherein said at least one pharmaceutical agent, said carrier and said anti-bacterial agent are suitable for intracameral injection into said eye.
PCT/US2008/000696 2006-12-12 2008-01-18 Eye medication formulation with antibacterial agent WO2008074036A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1323206P 2006-12-12 2006-12-12
US95941806A 2006-12-18 2006-12-18
US61/013,232 2007-12-12
US11/959,418 2007-12-18

Publications (1)

Publication Number Publication Date
WO2008074036A2 true WO2008074036A2 (en) 2008-06-19

Family

ID=39512488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/000696 WO2008074036A2 (en) 2006-12-12 2008-01-18 Eye medication formulation with antibacterial agent

Country Status (1)

Country Link
WO (1) WO2008074036A2 (en)

Similar Documents

Publication Publication Date Title
KR101453601B1 (en) Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
EP1924309A1 (en) Ophthalmic syringe
EP1140016A1 (en) Composition set and kit for use in intraocular surgery
CN109561985A (en) Improve the composition and method of operation for glaucoma successful instance using Nintedanib
Donnenfeld et al. Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery
CN109996814B (en) Multi-kinase inhibitors and their use in ocular fibrosis
Byrd et al. Medical control of intraocular pressure after cataract surgery
Silverstone et al. Prophylactic treatment of intraocular pressure elevations after neodymium: YAG laser posterior capsulotomies and extracapsular cataract extractions with levobunolol
Inagaki et al. Bacterial culture after three sterilization methods for cataract surgery
Lee et al. Advances in ophthalmic drug delivery technology for postoperative management after cataract surgery
US20090156587A1 (en) Eye Medication Formulation with Antibacterial Agent
US20040013729A1 (en) Single-drop multiple-agent composition for topical delivery to the eye
AU2008289347B2 (en) Compositions and methods for modulating endophthalmitis using fluoroquinolones
WO2008074036A2 (en) Eye medication formulation with antibacterial agent
Fauser et al. Intraocular inflammation after intravitreal ranibizumab injections.
WO1999040933A1 (en) Use of hyaluronidase to reduce viscoelastic related increases in intraocular pressure
Espiritu et al. Efficacy and Tolerability of a Combined Moxifloxacin/Dexamethasone Formulation for Topical Prophylaxis in Phacoemulsification: An Open‐Label Single‐Arm Clinical Trial
TW202033186A (en) Composition for ophthalmic use
Ellakwa et al. Evaluation of nepafenac eye drops in prevention of macular edema following cataract surgery
Yeom et al. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd: YAG laser posterior capsulotomy
CN115554297B (en) Novel medical application of cytisine and pharmaceutical preparation thereof
Hosny et al. Combined lidocaine 1% and hydroxypropyl methylcellulose 2.25% as a single anesthetic/viscoelastic agent in phacoemulsification
WO2023039168A1 (en) Use of verteporfin to modulate wound healing after an ocular surgical procedure or ocular injury
RU2624901C2 (en) Agent for application anaesthesia with antiseptic, optical-keratoprotective properties and method for use thereof in ophthalmology
WO2003086465A1 (en) Drugs for myopia correction surgery

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 684/CHENP/2008

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08724623

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE